What is the current valuation of the diabetes market in 2025?

The diabetes market valuation is approximately 100.0 USD Billion in 2024, and it is expected to grow significantly by 2035. Read More

Which companies are the key players in the diabetes market?

Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, Merck & Co., AbbVie, Eli Lilly and Company, Johnson & Johnson, AstraZeneca, and Roche. Read More

What is the projected market size for the diabetes market by 2035?

The diabetes market is projected to reach 150.0 USD Billion by 2035, indicating substantial growth. Read More

What is the expected CAGR for the diabetes market from 2025 to 2035?

The expected CAGR for the diabetes market during the forecast period 2025 - 2035 is 3.75%. Read More

How is the diabetes market segmented by type of diabetes?

The market segments by type of diabetes include Type 1 Diabetes valued at 10.0 to 15.0 USD Billion, Type 2 Diabetes at 60.0 to 90.0 USD Billion, and others. Read More

What are the primary treatment methods in the diabetes market?

Primary treatment methods include Insulin Therapy valued at 30.0 to 45.0 USD Billion and Oral Medications at 25.0 to 35.0 USD Billion. Read More

How does the diabetes market segment by patient demographics?

The market segments by patient demographics include Adults valued at 50.0 to 75.0 USD Billion and Elderly at 20.0 to 30.0 USD Billion. Read More

What complications are associated with diabetes in the market?

Complications include Cardiovascular Disease valued at 30.0 to 45.0 USD Billion and Kidney Disease at 25.0 to 35.0 USD Billion. Read More

What are the market channels for diabetes products?

Market channels include Retail Pharmacies valued at 30.0 to 45.0 USD Billion and Hospitals at 25.0 to 35.0 USD Billion. Read More

What is the growth outlook for the diabetes market in the coming years?

The diabetes market is anticipated to experience steady growth, reaching 150.0 USD Billion by 2035, driven by increasing prevalence and treatment advancements. Read More

Diabetes Market

ID: MRFR/Pharma/2180-HCR

60 Pages

Vikita Thakur

Last Updated: May 14, 2026

Diabetes Market information, by Type (Type 1, Type 2, and Gestational diabetes), by Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others), by Devices (Blood glucose monitoring devices, Diabetes management devices, and others) by Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery and others) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type of Diabetes (USD Billion) | |
  1. 4.1.1 Type 1 Diabetes | |
  2. 4.1.2 Type 2 Diabetes | |
  3. 4.1.3 Gestational Diabetes | |
  4. 4.1.4 LADA | |
  5. 4.1.5 MODY |
2. 4.2 Healthcare, BY Treatment Method (USD Billion) | |
  1. 4.2.1 Insulin Therapy | |
  2. 4.2.2 Oral Medications | |
  3. 4.2.3 Dietary Management | |
  4. 4.2.4 Continuous Glucose Monitoring | |
  5. 4.2.5 Exercise Regimens |
3. 4.3 Healthcare, BY Patient Demographics (USD Billion) | |
  1. 4.3.1 Children | |
  2. 4.3.2 Adults | |
  3. 4.3.3 Elderly | |
  4. 4.3.4 Pregnant Women | |
  5. 4.3.5 Obese Individuals |
4. 4.4 Healthcare, BY Complications (USD Billion) | |
  1. 4.4.1 Cardiovascular Disease | |
  2. 4.4.2 Neuropathy | |
  3. 4.4.3 Retinopathy | |
  4. 4.4.4 Kidney Disease | |
  5. 4.4.5 Foot Problems |
5. 4.5 Healthcare, BY Market Channel (USD Billion) | |
  1. 4.5.1 Retail Pharmacies | |
  2. 4.5.2 Online Pharmacies | |
  3. 4.5.3 Hospitals | |
  4. 4.5.4 Clinics | |
  5. 4.5.5 Diabetes Care Centers |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Novo Nordisk (DK) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Sanofi (FR) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Merck & Co. (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AbbVie (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Eli Lilly and Company (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Johnson & Johnson (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 AstraZeneca (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Roche (CH) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE OF DIABETES |
7. 6.4 US MARKET ANALYSIS BY TREATMENT METHOD |
8. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
9. 6.6 US MARKET ANALYSIS BY COMPLICATIONS |
10. 6.7 US MARKET ANALYSIS BY MARKET CHANNEL |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE OF DIABETES |
12. 6.9 CANADA MARKET ANALYSIS BY TREATMENT METHOD |
13. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
14. 6.11 CANADA MARKET ANALYSIS BY COMPLICATIONS |
15. 6.12 CANADA MARKET ANALYSIS BY MARKET CHANNEL |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY TYPE OF DIABETES |
18. 6.15 GERMANY MARKET ANALYSIS BY TREATMENT METHOD |
19. 6.16 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
20. 6.17 GERMANY MARKET ANALYSIS BY COMPLICATIONS |
21. 6.18 GERMANY MARKET ANALYSIS BY MARKET CHANNEL |
22. 6.19 UK MARKET ANALYSIS BY TYPE OF DIABETES |
23. 6.20 UK MARKET ANALYSIS BY TREATMENT METHOD |
24. 6.21 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
25. 6.22 UK MARKET ANALYSIS BY COMPLICATIONS |
26. 6.23 UK MARKET ANALYSIS BY MARKET CHANNEL |
27. 6.24 FRANCE MARKET ANALYSIS BY TYPE OF DIABETES |
28. 6.25 FRANCE MARKET ANALYSIS BY TREATMENT METHOD |
29. 6.26 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
30. 6.27 FRANCE MARKET ANALYSIS BY COMPLICATIONS |
31. 6.28 FRANCE MARKET ANALYSIS BY MARKET CHANNEL |
32. 6.29 RUSSIA MARKET ANALYSIS BY TYPE OF DIABETES |
33. 6.30 RUSSIA MARKET ANALYSIS BY TREATMENT METHOD |
34. 6.31 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
35. 6.32 RUSSIA MARKET ANALYSIS BY COMPLICATIONS |
36. 6.33 RUSSIA MARKET ANALYSIS BY MARKET CHANNEL |
37. 6.34 ITALY MARKET ANALYSIS BY TYPE OF DIABETES |
38. 6.35 ITALY MARKET ANALYSIS BY TREATMENT METHOD |
39. 6.36 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
40. 6.37 ITALY MARKET ANALYSIS BY COMPLICATIONS |
41. 6.38 ITALY MARKET ANALYSIS BY MARKET CHANNEL |
42. 6.39 SPAIN MARKET ANALYSIS BY TYPE OF DIABETES |
43. 6.40 SPAIN MARKET ANALYSIS BY TREATMENT METHOD |
44. 6.41 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
45. 6.42 SPAIN MARKET ANALYSIS BY COMPLICATIONS |
46. 6.43 SPAIN MARKET ANALYSIS BY MARKET CHANNEL |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE OF DIABETES |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY TREATMENT METHOD |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY COMPLICATIONS |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY MARKET CHANNEL |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY TYPE OF DIABETES |
54. 6.51 CHINA MARKET ANALYSIS BY TREATMENT METHOD |
55. 6.52 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
56. 6.53 CHINA MARKET ANALYSIS BY COMPLICATIONS |
57. 6.54 CHINA MARKET ANALYSIS BY MARKET CHANNEL |
58. 6.55 INDIA MARKET ANALYSIS BY TYPE OF DIABETES |
59. 6.56 INDIA MARKET ANALYSIS BY TREATMENT METHOD |
60. 6.57 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
61. 6.58 INDIA MARKET ANALYSIS BY COMPLICATIONS |
62. 6.59 INDIA MARKET ANALYSIS BY MARKET CHANNEL |
63. 6.60 JAPAN MARKET ANALYSIS BY TYPE OF DIABETES |
64. 6.61 JAPAN MARKET ANALYSIS BY TREATMENT METHOD |
65. 6.62 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
66. 6.63 JAPAN MARKET ANALYSIS BY COMPLICATIONS |
67. 6.64 JAPAN MARKET ANALYSIS BY MARKET CHANNEL |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE OF DIABETES |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY TREATMENT METHOD |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY COMPLICATIONS |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY MARKET CHANNEL |
73. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE OF DIABETES |
74. 6.71 MALAYSIA MARKET ANALYSIS BY TREATMENT METHOD |
75. 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
76. 6.73 MALAYSIA MARKET ANALYSIS BY COMPLICATIONS |
77. 6.74 MALAYSIA MARKET ANALYSIS BY MARKET CHANNEL |
78. 6.75 THAILAND MARKET ANALYSIS BY TYPE OF DIABETES |
79. 6.76 THAILAND MARKET ANALYSIS BY TREATMENT METHOD |
80. 6.77 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
81. 6.78 THAILAND MARKET ANALYSIS BY COMPLICATIONS |
82. 6.79 THAILAND MARKET ANALYSIS BY MARKET CHANNEL |
83. 6.80 INDONESIA MARKET ANALYSIS BY TYPE OF DIABETES |
84. 6.81 INDONESIA MARKET ANALYSIS BY TREATMENT METHOD |
85. 6.82 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
86. 6.83 INDONESIA MARKET ANALYSIS BY COMPLICATIONS |
87. 6.84 INDONESIA MARKET ANALYSIS BY MARKET CHANNEL |
88. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE OF DIABETES |
89. 6.86 REST OF APAC MARKET ANALYSIS BY TREATMENT METHOD |
90. 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
91. 6.88 REST OF APAC MARKET ANALYSIS BY COMPLICATIONS |
92. 6.89 REST OF APAC MARKET ANALYSIS BY MARKET CHANNEL |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY TYPE OF DIABETES |
95. 6.92 BRAZIL MARKET ANALYSIS BY TREATMENT METHOD |
96. 6.93 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
97. 6.94 BRAZIL MARKET ANALYSIS BY COMPLICATIONS |
98. 6.95 BRAZIL MARKET ANALYSIS BY MARKET CHANNEL |
99. 6.96 MEXICO MARKET ANALYSIS BY TYPE OF DIABETES |
100. 6.97 MEXICO MARKET ANALYSIS BY TREATMENT METHOD |
101. 6.98 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
102. 6.99 MEXICO MARKET ANALYSIS BY COMPLICATIONS |
103. 6.100 MEXICO MARKET ANALYSIS BY MARKET CHANNEL |
104. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE OF DIABETES |
105. 6.102 ARGENTINA MARKET ANALYSIS BY TREATMENT METHOD |
106. 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
107. 6.104 ARGENTINA MARKET ANALYSIS BY COMPLICATIONS |
108. 6.105 ARGENTINA MARKET ANALYSIS BY MARKET CHANNEL |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF DIABETES |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT METHOD |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY COMPLICATIONS |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY MARKET CHANNEL |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF DIABETES |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT METHOD |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY COMPLICATIONS |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY MARKET CHANNEL |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF DIABETES |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT METHOD |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY COMPLICATIONS |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY MARKET CHANNEL |
125. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE OF DIABETES |
126. 6.123 REST OF MEA MARKET ANALYSIS BY TREATMENT METHOD |
127. 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
128. 6.125 REST OF MEA MARKET ANALYSIS BY COMPLICATIONS |
129. 6.126 REST OF MEA MARKET ANALYSIS BY MARKET CHANNEL |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY TYPE OF DIABETES, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY TYPE OF DIABETES, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY COMPLICATIONS, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY COMPLICATIONS, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY MARKET CHANNEL, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY MARKET CHANNEL, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE OF DIABETES, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY TREATMENT METHOD, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY COMPLICATIONS, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY MARKET CHANNEL, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type of Diabetes (USD Billion, 2025-2035)

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
LADA
MODY

Healthcare By Treatment Method (USD Billion, 2025-2035)

Insulin Therapy
Oral Medications
Dietary Management
Continuous Glucose Monitoring
Exercise Regimens

Healthcare By Patient Demographics (USD Billion, 2025-2035)

Children
Adults
Elderly
Pregnant Women
Obese Individuals

Healthcare By Complications (USD Billion, 2025-2035)

Cardiovascular Disease
Neuropathy
Retinopathy
Kidney Disease
Foot Problems

Healthcare By Market Channel (USD Billion, 2025-2035)

Retail Pharmacies
Online Pharmacies
Hospitals
Clinics
Diabetes Care Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓